又有一家上市公司被证监会立案。 据证监会网站2月13日消息，2026年1月6日，深圳英集芯科技股份有限公司（简称"英集芯"，证券简称：688209）在上证E互动平台人为策划"自问自答"， 信息披露构成误导性陈述。近日，证监会已对英集芯立案调查。下一步，将在全面调查的基础上依法处理，切实维护市场健康发展。 公司与参股公司精芯唯尔（常州）电子科技有限公司（简称"精芯唯尔"）共同推出的IPA1299是一款支持8通道低噪声设计，24位同步采样模数转换器芯片 （ADC），主要应用于脑电图（EEG）、心电图（ECG）和肌电图（EMG）， 该产品主要特点在于可实现高精度信号采集功能，可应用于非侵入式脑机 接口领域。该产品用于人体生物电信号的高精度测量，其适用于各种可穿戴式设备应用场景，技术路线与当前国际上的侵入式脑机接口存在显著技术路径 差异。截至公告披露日，该产品在非侵入式脑机接口领域尚处于市场培育期，尚未实现规模化销售，暂未对公司业绩产生重大影响，未来销售情况存在不 确定性。 综合自：证监会网站、公司公告 责编：李丹 校对：王锦程 版权声明 随后，英集芯发布公告称，公司于2026年2月13日收到证监会下发的《立案告知书 ...

Core Viewpoint - The company has strategically invested in Hangzhou Haoshi Tianhui Technology Co., Ltd., acquiring a 16% stake as the sole investor in its latest financing round, marking another exploration in the non-invasive brain-computer interface sector following its 2025 investment in Qingshi Yongjuan [1] Group 1: Company Overview - Haoshi Tianhui is an innovative high-tech enterprise focused on artificial intelligence in the medical field, with a founding team that has overseas entrepreneurial experience and strong industry expertise [1] - The company has developed a diverse product matrix that includes applications in mental health, cardiovascular monitoring, and imaging diagnostics [1] Group 2: Product and Technology - Haoshi Tianhui's self-developed medical-grade non-invasive brain-computer interface and mental health assessment devices can accurately evaluate emotional issues such as depression and anxiety, integrating music therapy interventions into a comprehensive service model [1] - The products are designed for various settings, including hospitals, schools, health check centers, and mental health institutions, providing objective and efficient assessments compared to traditional evaluation methods [1] Group 3: Regulatory and Market Plans - The company obtained a Class II medical device registration certificate in November 2025 for its products aimed at detecting mental health issues, with plans to promote and sell these products in the domestic market starting in 2026 [1]

Group 1 - The core stock price of Beilu Pharmaceutical (300016) closed at 9.44 yuan on January 12, 2026, with an increase of 2.39% and a turnover rate of 8.34%, resulting in a trading volume of 469,100 shares and a transaction amount of 439 million yuan [1] - The company reported significant revenue growth from its export products, primarily contrast agents and raw materials, covering markets in South America, Africa, and Asia [2] - The overall gross margin for the company's overseas business in 2024 was only 17.57%, significantly lower than the disclosed gross margin of 49.2% for contrast agents, attributed to a higher proportion of raw materials in the export revenue structure [2] Group 2 - On January 12, the net inflow of main funds into Beilu Pharmaceutical was 7.25 million yuan, indicating positive engagement from major investors [3] - The net inflow of speculative funds was 4.87 million yuan, while retail investors experienced a net outflow of 12.12 million yuan [4]

Core Viewpoint - The approval of the medical device registration certificate for the Mindray brain-computer interface transcranial magnetic stimulation device marks a significant breakthrough in advanced medical technology for the company, indicating a substantial step towards the industrial application of non-invasive brain-computer interfaces and opening new avenues for future technological expansion and revenue growth [1] Group 1 - The Jiangsu Provincial Drug Administration has granted a medical device registration certificate to Mindray for its brain-computer interface transcranial magnetic stimulation device [1] - This achievement signifies an important milestone in the field of advanced medical technology for the company [1] - The development paves the way for the practical application of non-invasive brain-computer interfaces, enhancing the company's growth potential [1]

Core Viewpoint - The company, 英集芯, has introduced a new product, IPA1299, which is a low-noise, 24-bit synchronous sampling ADC chip designed for non-invasive brain-machine interface applications, although it is still in the market cultivation phase and has not yet achieved significant sales impact on the company's performance [1] Product Overview - The IPA1299 chip supports 8-channel low-noise design and is primarily used for electroencephalogram (EEG), electrocardiogram (ECG), and electromyogram (EMG) applications [1] - The product features high-precision signal acquisition capabilities, making it suitable for various wearable device applications [1] - The technology path of IPA1299 significantly differs from current invasive brain-machine interfaces available internationally [1] Market Status - As of the announcement date, the IPA1299 is still in the market cultivation phase and has not yet achieved large-scale sales [1] - The future sales situation of the product remains uncertain and has not had a major impact on the company's financial performance to date [1]

Investment Rating - The investment rating for the company is "Accumulate" [4]. Core Insights - The company achieved a revenue of 326 million yuan in the first three quarters of 2025, representing a year-on-year growth of 11.58%, and a net profit attributable to the parent company of 102 million yuan, up 30.68% year-on-year [1][4]. - The core business of rehabilitation is steadily growing, while new emerging businesses in aesthetic medicine and urology are being developed, creating a multi-layered business structure [1]. - The mental rehabilitation business is benefiting from policy support and market demand, maintaining double-digit growth, while the pelvic floor rehabilitation business is experiencing single-digit growth due to product upgrades [1][2]. Financial Performance Summary - For the first three quarters of 2025, the company reported a revenue of 326 million yuan, with a net profit of 102 million yuan and a non-recurring net profit of 94 million yuan [1]. - The company expects net profits for 2025, 2026, and 2027 to be 133 million yuan, 165 million yuan, and 184 million yuan, respectively, with year-on-year growth rates of 30.1%, 24.0%, and 11.8% [2][3]. - The sales, management, and R&D expense ratios for the first three quarters of this year were 18.77%, 10.03%, and 9.74%, respectively, showing a decrease compared to the previous year [2].

Core Insights - Neuralink has completed a $650 million Series E funding round, setting a new record in the brain-computer interface (BCI) sector, bringing its total funding to over $1.3 billion, which is significant compared to the global BCI market size of $2.6 billion in 2024 [1][2] - Despite substantial funding, Neuralink faces high operational costs, burning several hundred million dollars annually without a clear path to commercialization [2][3] - The BCI industry is experiencing a funding boom, with nearly 100 financing events in the past five years in China alone, totaling over 10 billion yuan, indicating strong investor interest [3][4] Funding Landscape - Neuralink's funding history includes multiple rounds, with significant contributions from major investors like ARK Invest and Sequoia Capital in the latest round [2] - The BCI sector has seen a 30% increase in financing events in China from January to November 2025, with notable records set by companies like JieTi Medical [5] - Government funding is becoming increasingly important, with various local and national policies supporting BCI development, including a 10 billion yuan fund in Tianjin [6][7] Market Dynamics - The BCI market is characterized by a lack of stable commercialization and profitability, leading many companies to face survival challenges [3][4] - Investors are shifting focus from upstream technology to practical clinical applications and commercialization capabilities, indicating a maturation of the investment landscape [6] - The potential applications of BCI technology, such as restoring vision or mobility, present significant market opportunities, attracting early investments [4] Product Development and Commercialization - Companies are adopting a "laying eggs along the way" strategy, focusing on both research and consumer applications to maintain cash flow [9][10] - Non-invasive BCIs are targeting consumer healthcare markets, while invasive BCIs are focusing on research applications due to the complexity of clinical scenarios [10][12] - Successful commercialization examples include products like the intelligent bionic hand from QiangNerve Technology, which has seen rapid sales growth [11] Future Outlook - 2025 is anticipated to be a pivotal year for the BCI industry in China, with significant clinical advancements expected [15] - Challenges remain in signal processing, material compatibility, and market education, which could delay widespread commercialization [16] - Companies must balance short-term survival with long-term innovation to thrive in the evolving BCI landscape [18][19]

Core Insights - 麦澜德 is focusing on the development and commercialization of non-invasive brain-computer interface (BCI) technology, integrating it with existing technologies and clinical scenarios [1] Group 1: Clinical Directions and Technology Development - The company has developed a closed-loop system for cognitive function intervention, which includes four modules: emotional recognition, emotional interaction, cognitive assessment, and cognitive intervention, currently in multi-center clinical validation [2] - In the field of motor function rehabilitation, 麦澜德 has innovatively combined soft exoskeleton hand functions with EEG devices to create a brain-machine hand training system, showing preliminary effectiveness superior to traditional interventions [2] - For mental and psychosomatic disease regulation, the company is developing a multi-modal brain physiological signal monitoring platform in collaboration with Zhejiang University and other institutions, aiming to create portable products for monitoring brain states [2] Group 2: Technical Advantages and Ecosystem - 麦澜德's core advantages lie in three areas: multi-modal BCI technology for precise screening and personalized treatment, central-peripheral closed-loop technology with early multi-center clinical trials, and breakthroughs in cognitive impairment and emotional interaction [3] - The company has established a collaborative ecosystem involving universities, hospitals, and enterprises, ensuring that research and development align with clinical needs and facilitating resource sharing [3] Group 3: Market Promotion and Competitive Landscape - 麦澜德 has initiated preliminary cooperation with several hospitals in Jiangsu Province and southwestern regions, with some devices already in use at leading hospitals [4] - The competitive landscape in the BCI field is dominated by non-invasive companies, where the speed of obtaining registration certificates and market promotion capabilities are key factors [4] - The company aims to maintain its competitive edge by focusing on core technology research and clinical transformation [4]

Core Insights - The article discusses the competition between Sam Altman, CEO of OpenAI, and Elon Musk in the brain-computer interface (BCI) sector, highlighting the recent developments at Merge Labs, a company co-founded by Altman [1][2][5]. Company Developments - Merge Labs has recruited Mikhail Shapiro, a prominent researcher from Caltech, known for his work in non-invasive brain imaging and gene therapy [1][5][7]. - Altman is expected to serve as the chairman of Merge Labs, while Shapiro is anticipated to play a key leadership role in the company [5]. - Merge Labs is reportedly in discussions for a $250 million funding round led by OpenAI, which would value the company at $850 million [5]. Technology Approach - Merge Labs aims to develop a non-invasive brain-computer interface using "gene therapy + ultrasound" methods, contrasting with Neuralink's invasive techniques [5][11]. - Shapiro's research focuses on using ultrasound to interact with the brain without the need for surgical procedures, which is a significant departure from Neuralink's approach [7][12]. Industry Context - The article outlines the ongoing debate between invasive and non-invasive BCI technologies, with the former posing higher risks and potential complications [12]. - Altman has publicly expressed his preference for non-invasive methods, indicating a strategic direction for Merge Labs that may influence the future of human-AI integration [5][12].

Summary of Key Points from Conference Call Records Company and Industry Overview - **Company**: Xiangyu Medical - **Industry**: Brain-Computer Interface (BCI) Technology Core Insights and Arguments - **Focus on Non-Invasive BCI Technology**: Xiangyu Medical specializes in non-invasive brain-computer interface technology, developing five major research and development systems, including BCI acquisition devices, algorithms, and rehabilitation products, with plans to launch related products between late 2025 and 2026 [1][2] - **Applications in Rehabilitation**: The primary applications of Xiangyu Medical's non-invasive BCI products are in rehabilitation, targeting post-operative recovery, high-level paraplegia, Alzheimer's disease, and other clinical challenges through a multi-channel wireless EEG acquisition system and seven algorithms for high-precision signal acquisition and processing [1][4] - **Self-Developed Hardware**: The company has developed a complete set of self-researched chips, electrodes, and acquisition devices, obtaining two Class II medical device registration certificates, which establish a solid foundation and high barriers to entry in the industry [1][5] - **Government Support**: The Ministry of Industry and Information Technology's implementation opinions on promoting innovation in the brain interface industry provide top-level design and reduce policy uncertainty, which Xiangyu Medical is actively leveraging to accelerate product launch processes [1][8] Additional Important Content - **Clinical Applications and Collaborations**: As of the latest statistics, 87 hospitals have applied Xiangyu Medical's BCI products, utilizing various cooperation models, including research project collaborations and the establishment of BCI wards [10] - **Market Commercialization Stage**: The commercialization of BCI products is still in its early stages, with few certified products on the market. Xiangyu Medical plans to launch 27 products in 2025 and potentially 70-80 products in 2026 [9][14] - **Technological Advancements**: The company has achieved breakthroughs in hardware development, including high-precision, high-signal quality acquisition devices, and various electrode models to meet different customer needs [5][11] - **Future Growth and Revenue Projections**: Xiangyu Medical is optimistic about rapid revenue growth in the coming years, with over 100 devices shipped, valued conservatively at 200-300 million yuan, expected to convert into sales revenue depending on certification progress and hospital procurement rhythms [14] Competitive Landscape - **Other Companies in the BCI Field**: Aipeng Medical is also active in the BCI sector, focusing on brain state monitoring systems, insomnia treatment systems, and ADHD behavior management systems, utilizing AI technology to enhance product competitiveness [3][15][17] - **Market Potential for Cognitive Disorders**: The market potential for cognitive disorders, particularly Alzheimer's disease, is significant, with approximately 43.77 million patients in China, indicating a vast opportunity for BCI applications in this area [33] Challenges and Future Directions - **Technical Bottlenecks**: The industry faces challenges such as signal-to-noise ratio, packaging processes, and the need for multi-modal information fusion, which are critical for future development [31][45] - **Regulatory and Market Dynamics**: The current regulatory environment and market dynamics, including the need for certification and pricing strategies, will significantly impact the commercialization and adoption of BCI products [40][41] This summary encapsulates the key points from the conference call records, highlighting the strategic direction, technological advancements, market potential, and challenges faced by Xiangyu Medical and the broader BCI industry.